CFCorinna Friedrich

Corinna Friedrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corinna Friedrich has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer

    by Simon Schallenberg, Gabriel Dernbach, Sharon Ruane, Philipp Jurmeister, Cornelius Böhm, Kai Standvoss, Sandip Ghosh, Marco Frentsch, Mihnea P. Dragomir, Philipp G. Keyl, et al.

    Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multiplex immunofluorescence imaging and multimodal machine learning to characterize the complex cellular relationships of 43 cell phenotypes in the tumor microenvironment in a real-world retrospective cohort of 1168 non-small cell lung cancer patients from two large German cancer centers. The model identifies cell niches associated with survival and achieves a 14% and 47% improvement in risk stratification in the two main non-small cell lung cancer subtypes, lung adenocarcinoma and squamous cell carcinoma, respectively, combining niche patterns with conventional cancer staging. Our results show that complex immune cell niche patterns identify potentially undertreated high-risk patients qualifying for adjuvant therapy. Our approach highlights the potential of artificial intelligence powered multiplex imaging analyses to better understand the contribution of the tumor microenvironment to cancer progression and to improve risk stratification and treatment selection in non-small cell lung cancer.


  • Open Access

    Ubiquitin-Proteasome System Dysregulation in Alzheimer’s Disease Impacts Protein Abundance

    by Mahlon Collins, Corinna Friedrich, Megan Elcheikhali, Peyton Stewart, Jason Derks, Theresa Connors-Stewart, Kirsten Altig, Alexandra Melloni, Aleksandra Petelski, Derek Oakley, et al.

    Alzheimer’s disease (AD) is a relentlessly progressive, fatal neurodegenerative disorder that results in widespread protein dysfunctions. However, the full extent of aberrant proteomic changes in AD and their impact remains unknown, in part, because of the challenges of comprehensively measuring the proteome. Here, we used plexDIA, an approach that provides deep proteomic coverage and high throughput by parallelizing the acquisition of peptides and samples, to characterize proteomic changes in AD. Using human dorsolateral prefrontal cortex tissue, we identified 281 differentially abundant proteins in AD. By systematically analyzing compartment and protein complex-specific shifts in protein abundance, we identified an AD-specific decrease in levels of the 20S proteasome, the catalytic core of the cell’s primary protein degradation pathway. This alteration was accompanied by widespread decreases in proteasome subunit stoichiometries. Many proteasome substrate proteins were negatively correlated with 20S levels and increased in AD, suggesting that reduced 20S levels leads to abnormal protein accumulation. By analyzing proteins increased in AD, we identify key properties of such proteins: They have fast degradation rates, they contain signal sequences that allow them to be targeted for proteasomal degradation, and they are targeted by quality control pathways that recognize mislocalized proteins. Changes in these gene products at the protein and mRNA levels were highly discordant, providing additional evidence for increased protein abundance driven by impaired clearance. We also identified coherent sets of ubiquitin system enzymes, proteins that target substrates for proteasomal degradation, whose levels robustly discriminate AD from non-AD samples. One subset exhibited consistent increases in AD, while another, which contained the tau E3 ligase Cul5, exhibited consistent decreases, revealing complex changes in the ubiquitin system in AD. Taken together, our results suggest that decreased ubiquitin-proteasome system capacity and impaired clearance of short-lived and mislocalized proteins contribute substantially to proteopathic burden in AD.


  • Open Access

    PSMtags improve peptide sequencing and throughput in sensitive proteomics

    by Harrison Specht, Maddy Yeh, Sarah Sipe, David Barnes-Seeman, Mark Adamo, Kevin McDonnell, Michael P. Agius, Corinna Friedrich, Wai Kit Pang, Yanchang Huang, et al.

    Mass spectrometry-based proteomics enables comprehensive characterization of proteins, but label-free approaches are challenging to scale to thousands of samples per day (SPD). Multiplexed data-independent approaches (plexDIA) can increase throughput but lack the mass tags to enable it. Here, we systematically screened a library of 576 compounds and identified several small molecules that, when conjugated to peptides, improve their detection and sequence identification. The lead molecule, PSMtag, substantially increases the detection of fragment b-ions, which increases the confidence of sequence identification and enhances de novo sequencing. PSMtags allow 9-plexDIA, using only stable isotopes of carbon, oxygen and nitrogen. As a result, it allows increasing sample throughput for plexDIA workflows. We demonstrate 1,130 SPD with 9-plexDIA from single-cell-level human proteomes, acquiring 27,520 protein datapoints in the same time label-free methods acquire 3,216. Our approach constitutes an expandable framework for developing mass tags to overcome existing limitations in multiplexed proteomics.


  • Open Access

    Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories

    by Corinna Friedrich, Simon Schallenberg, Marieluise Kirchner, Matthias Ziehm, Sylvia Niquet, Mohamed Haji, Christin Beier, Jens Neudecker, Frederick Klauschen, Philipp Mertins

    Formalin-fixed paraffin-embedded (FFPE) tissues are a valuable resource for retrospective clinical studies. Here, we evaluate the feasibility of (phospho-)proteomics on FFPE lung tissue regarding protein extraction, quantification, pre-analytics, and sample size. After comparing protein extraction protocols, we use the best-performing protocol for the acquisition of deep (phospho-)proteomes from lung squamous cell and adenocarcinoma with >8,000 quantified proteins and >14,000 phosphosites with a tandem mass tag (TMT) approach. With a microscaled approach, we quantify 7,000 phosphosites, enabling the analysis of FFPE biopsies with limited tissue amounts. We also investigate the influence of pre-analytical variables including fixation time and heat-assisted de-crosslinking on protein extraction efficiency and proteome coverage. Our improved workflows provide quantitative information on protein abundance and phosphosite regulation for the most relevant oncogenes, tumor suppressors, and signaling pathways in lung cancer. Finally, we present general guidelines to which methods are best suited for different applications, highlighting TMT methods for comprehensive (phospho-)proteome profiling for focused clinical studies and label-free methods for large cohorts.